01:40 , Aug 18, 2018 |  BioCentury  |  Regulation

Pediatric push

FDA has endorsed extrapolation of therapeutic efficacy from adults to children for new drugs to treat partial onset seizures in a draft guidance and is now discussing in public meetings whether the approach can be...
21:53 , Aug 17, 2018 |  BioCentury  |  Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
20:34 , Aug 17, 2018 |  BC Extra  |  Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

China's State Medical Insurance Administration announced 18 cancer drugs that will be included in 2018 medical insurance access negotiations. Companies with drugs on the list will now enter into negotiations to include the drugs on...
17:25 , Aug 17, 2018 |  BC Week In Review  |  Financial News

MD Anderson launches neuroscience newco with $31M series A

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York, N.Y.), which launched Aug. 13 with a $31 million series A round. Eli Lilly...
17:24 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

J&J, ViiV's two-drug regimen meets in Phase III for maintenance treatment of HIV-1 infection

ViiV Healthcare Ltd. (Brentford, U.K.) and Johnson & Johnson (NYSE:JNJ) said a two-drug regimen comprising cabotegravir and Edurant rilpivirine met the primary endpoint in the Phase III ATLAS trial as maintenance treatment in HIV-1-infected adults...
16:05 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Mouse studies suggest inhibiting JAK-1 and JAK-2, RAG2 or IL-6 could help treat Peutz-Jeghers syndrome, which involves the formation of benign gastrointestinal polyps. In a mouse model of the disease, systemic knockout of RAG2...
10:03 , Aug 13, 2018 |  BC Extra  |  Financial News

MD Anderson launches neuroscience newco with $31M series A

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York, N.Y.), which launched Monday with a $31 million series A round. Participating in the...
18:50 , Aug 10, 2018 |  BC Week In Review  |  Company News

Janssen, Immune Biosolutions partner to discover, develop antibodies for cancer

Immune Biosolutions Inc. (Sherbrooke, Quebec) and the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to discover and develop antibodies against multiple undisclosed cancer targets. The partners will utilize Immune Biosolutions' Nebula antibody...
06:11 , Aug 10, 2018 |  BC Week In Review  |  Company News

Emergent acquiring vaccine company PaxVax

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire vaccine company PaxVax Inc. (Redwood City, Calif.) for $270 million in cash. Emergent will gain Vivotif and Vaxchora, which PaxVax markets to prevent typhoid fever and cholera, respectively....
22:00 , Aug 9, 2018 |  BC Extra  |  Politics & Policy

China releases list of overseas drugs eligible for Priority Review

China’s Drug Evaluation Center posted a list of 48 drugs already approved in the U.S., EU or Japan that could be eligible for Priority Review in China. Last December, China's State Drug Administration released guidance to...